drugset / Trial / NCT07341152

A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

NCT07341152

Phase 1 Completed 14 enrolled Latigo Biotherapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-center, open-label, part-randomized, crossover study in 14 healthy participants to assess the PK and safety profile of an SDD formulation of LTG-001 and two crystalline LTG-001 Instant Release tablet formulations, one of which will also be assessed at a differing dose level.

Timeline

Start
2025-10-06
Primary completion
2025-11-17
Completion
2025-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject LTG-001 Unknown

Indications

No indication recorded.